Progenics Pharmaceuticals (PGNX) Posts Narrower than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported Q3 loss of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $6.5 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Reading (RDI) Tops Q2 EPS by 4c
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
